Durvalumab plus tremelimumab influence on response to subsequent treatments in patients with neuroendocrine neoplasms (NENs) of gastroenteropancreatic and lung origins: Results from the phase II DUNE trial (GETNE 1601)

被引：1

作者：

Hernando, J. ^{[1
]}

Manzano, J. L. ^{[2
]}

Teule, A. ^{[3
]}

Lopez, C. ^{[4
]}

Garcia-Carbonero, R. ^{[5
]}

Benavent Vinuales, M. ^{[6
]}

Custodio, A. ^{[7
]}

Cubillo, A. ^{[8
]}

Alonso, V. ^{[9
]}

Alonso-Gordoa, T. ^{[10
]}

Carmona-Bayonas, A. ^{[11
]}

Crespo, G. ^{[12
]}

Blanco, M. ^{[13
]}

Jimenez-Fonseca, P. ^{[14
]}

Viudez, A. ^{[15
]}

La Casta, A. ^{[16
]}

Sevilla, I. ^{[17
]}

Llanos, M. ^{[18
]}

Segura, A. ^{[19
]}

Capdevila, J. ^{[1
]}

机构：

[1] Vall dHebron Univ Hosp, Vall dHebron Inst Oncol VHIO, Dept Med Oncol, Barcelona, Spain

[2] Inst Catala Oncol ICO Badalona, Hosp Germans Trias i Pujol, Dept Med Oncol, Badalona, Spain

[3] Inst Catala Oncol ICO IDIBELL, Med Oncol Dept, Lhospitalet De Llobregat, Spain

[4] Hosp Univ Marques Valdecilla, IDIVAL, Med Oncol Dept, Santander, Spain

[5] Hosp Univ 12 Octubre, Imas12, UCM CNIO, Med Oncol Dept, Madrid, Spain

[6] Univ Hosp Virgen Rocio, Inst Biomed Sevilla IBIS, Med Oncol Dept, Seville, Spain

[7] Hosp Univ La Paz, Dept Med Oncol, Madrid, Spain

[8] Hosp Univ HM Sanchinarro, Med Oncol Dept, Madrid, Spain

[9] Inst Invest Sanitaria Aragon IISA, Hosp Univ Miguel Servet, Dept Med Oncol, Zaragoza, Spain

[10] Hosp Univ Ramon & Cajal, Med Oncol, Madrid, Spain

[11] Hosp Univ Morales Meseguer, UMU, IMIB, Hematol & Med Oncol Dept, Murcia, Spain

[12] Complejo Asistencial Univ Burgos, Med Oncol Dept, Burgos, Spain

[13] Hosp Univ Gregorio Maranon, Med Oncol Dept, Madrid, Spain

[14] Hosp Univ Cent Asturias, ISPA, Med Oncol Dept, Oviedo, Spain

[15] Complejo Hosp Navarra, Medica Oncol Dept, Pamplona, Spain

[16] Hosp Univ Donostia, Dept Med Oncol, San Sebastian, Spain

[17] Hosp Univ Reg & Virgen Victoria Malaga, Inst Invest Biomed Malaga IBIMA, Invest Clin & Traslac Canc, Med Oncol Dept, Malaga, Spain

[18] Hosp Univ Canarias, Med Oncol Dept, San Cristobal la Laguna, Spain

[19] Hosp Univ Fe, Med Oncol Dept, Valencia, Spain

来源：

ANNALS OF ONCOLOGY | 2021年 / 32卷

关键词：

D O I：

10.1016/j.annonc.2021.08.181

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1099MO

引用

页码：S909 / S910

页数：2

共 31 条

[31] Analysis of early tumor shrinkage (ETS) and depth of response (DpR) in metastatic colorectal cancer (mCRC) patients (pts) treated with second-line FOLFIRI plus panitumumab (Pani) or bevacizumab (Bev): Results from a randomized phase II WJOG6210G trial
Izawa, Naoki
Shitara, Kohei
Masuishi, Toshiki
Denda, Tadamichi
Yamazaki, Kentaro
Moriwaki, Toshikazu
Okuda, Hiroyuki
Kondoh, Chihiro
Nishina, Tomohiro
Makiyama, Akitaka
Baba, Hideo
Yamaguchi, Hironori
Nakamura, Masato
Tsuji, Akihito
Esaki, Taito
Miyata, Yoshinori
Kotaka, Masahito
Yamanaka, Takeharu
Nakajima, Takako Eguchi
Muro, Kei
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)

← 1 2 3 4 →